Ashwani Verma
Stock Analyst at UBS
(2.05)
# 2,754
Out of 4,828 analysts
66
Total ratings
36.17%
Success rate
-3.91%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Buy | $137 → $152 | $115.71 | +31.36% | 8 | May 6, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $47 → $41 | $31.70 | +29.36% | 5 | May 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $55 → $48 | $34.06 | +40.95% | 2 | Apr 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $25 → $22 | $17.44 | +26.15% | 4 | Apr 28, 2025 | |
| ALKS Alkermes | Maintains: Neutral | $38 → $33 | $30.13 | +9.53% | 4 | Apr 28, 2025 | |
| CHRS Coherus BioSciences | Maintains: Neutral | $1.5 → $1.05 | $0.97 | +8.39% | 5 | Apr 24, 2025 | |
| JAZZ Jazz Pharmaceuticals | Upgrades: Buy | $145 → $179 | $97.78 | +83.06% | 6 | Mar 7, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $30 → $27 | $16.93 | +59.48% | 8 | Jan 30, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $30 → $34 | $36.17 | -6.00% | 2 | Jan 28, 2025 | |
| AVDL Avadel Pharmaceuticals | Maintains: Buy | $22 → $14 | $9.39 | +49.09% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $415 → $475 | $301.42 | +57.59% | 4 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $57.55 | +98.09% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $54 | $20.24 | +166.80% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $105 | $107.76 | -2.56% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $33.15 | -15.54% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $76 → $81 | $31.78 | +154.88% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $70.57 | -90.08% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $8.77 | +36.83% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.73 | +1,954.79% | 1 | Oct 11, 2022 | |
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $137 → $152
Current: $115.71
Upside: +31.36%
Cytokinetics
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $31.70
Upside: +29.36%
Harmony Biosciences Holdings
Apr 28, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $34.06
Upside: +40.95%
ACADIA Pharmaceuticals
Apr 28, 2025
Maintains: Buy
Price Target: $25 → $22
Current: $17.44
Upside: +26.15%
Alkermes
Apr 28, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $30.13
Upside: +9.53%
Coherus BioSciences
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $0.97
Upside: +8.39%
Jazz Pharmaceuticals
Mar 7, 2025
Upgrades: Buy
Price Target: $145 → $179
Current: $97.78
Upside: +83.06%
Teva Pharmaceutical Industries
Jan 30, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $16.93
Upside: +59.48%
Exelixis
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $34
Current: $36.17
Upside: -6.00%
Avadel Pharmaceuticals
Jan 13, 2025
Maintains: Buy
Price Target: $22 → $14
Current: $9.39
Upside: +49.09%
Jan 8, 2025
Maintains: Buy
Price Target: $415 → $475
Current: $301.42
Upside: +57.59%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $57.55
Upside: +98.09%
Aug 13, 2024
Maintains: Buy
Price Target: $55 → $54
Current: $20.24
Upside: +166.80%
Aug 6, 2024
Maintains: Buy
Price Target: $107 → $105
Current: $107.76
Upside: -2.56%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $33.15
Upside: -15.54%
Mar 18, 2024
Maintains: Buy
Price Target: $76 → $81
Current: $31.78
Upside: +154.88%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $70.57
Upside: -90.08%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $8.77
Upside: +36.83%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $0.73
Upside: +1,954.79%